Non-steroidal anti-inflammatory treatment in cancer cachexia: A systematic literature review

References

• Fearon KC. Cancer cachexia: Developing multimodal therapy for a multidimensional problem. Eur J Cancer 2008;44:1124–32.
   PubMed Web of Science ®Google Scholar
• Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, . Definition and classification of cancer cachexia: An international consensus. Lancet Oncol 2011;12:489–95.
   PubMed Web of Science ®Google Scholar
• Yavuzsen T, Davis MP, Walsh D, LeGrand S, Lagman R. Systematic review of the treatment of cancer-associated anorexia and weight loss. J Clin Oncol 2005;23: 8500–11.
   PubMed Web of Science ®Google Scholar
• Murphy KT, Lynch GS. Update on emerging drugs for cancer cachexia. Expert Opin Emerg Drugs 2009;14: 619–32.
   PubMed Web of Science ®Google Scholar
• Argiles JM, Moore-Carrasco R, Fuster G, Busquets S, Lopez-Soriano FJ. Cancer cachexia: The molecular mechanisms. Int J Biochem Cell Biol 2003;35:405–9.
   PubMed Web of Science ®Google Scholar
• Laviano A, Inui A, Meguid MM, Molfino A, Conte C, Rossi Fanelli F. NPY and brain monoamines in the pathogenesis of cancer anorexia. Nutrition 2008;24:802–5.
   PubMed Web of Science ®Google Scholar
• Madeddu C, Dessi M, Panzone F, Serpe R, Antoni G, Cau MC, . Randomized phase III clinical trial of a combined treatment with carnitine +celecoxib ± megestrol acetate for patients with cancer-related anorexia/cachexia syndrome. Clin Nutr Epub 2011 Nov 4.
   Google Scholar
• Lundholm K, Korner U, Gunnebo L, Sixt-Ammilon P, Fouladiun M, Daneryd P, . Insulin treatment in cancer cachexia: Effects on survival, metabolism, and physical functioning. Clin Cancer Res 2007;13:2699–706.
   PubMed Web of Science ®Google Scholar
• Daneryd P, Svanberg E, Korner U, Lindholm E, Sandstrom R, Brevinge H, . Protection of metabolic and exercise capacity in unselected weight-losing cancer patients following treatment with recombinant erythropoietin: A randomized prospective study. Cancer Res 1998;58: 5374–9.
   PubMed Web of Science ®Google Scholar
• Rogers ES, MacLeod RD, Stewart J, Bird SP, Keogh JW. A randomised feasibility study of EPA and Cox-2 inhibitor (Celebrex) versus EPA, Cox-2 inhibitor (Celebrex), resistance training followed by ingestion of essential amino acids high in leucine in NSCLC cachectic patients – ACCeRT study. BMC Cancer 2011;11:493.
   Google Scholar
• Induru RR, Lagman RL. Managing cancer pain: Frequently asked questions. Cleveland Clin J Med 2011;78:449–64.
   PubMed Web of Science ®Google Scholar
• Ghosh N, Chaki R, Mandal V, Mandal SC. COX-2 as a target for cancer chemotherapy. Pharmacol Report 2010;62:233–44.
   PubMed Web of Science ®Google Scholar
• Rothwell PM, Price JF, Fowkes FG, Zanchetti A, Roncaglioni MC, Tognoni G, . Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: Analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet Epub 2012 Mar 24.
   Google Scholar
• Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW, Mehta Z. Effect of daily aspirin on risk of cancer metastasis: A study of incident cancers during randomised controlled trials. Lancet Epub 2012 Mar 24.
   Google Scholar
• Higgins JPT GSe. Cochrane handbook for systematic reviews of interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. Available from: http://www.cochrane-handbook.org.2011.
   Google Scholar
• Gridelli C, Gallo C, Ceribelli A, Gebbia V, Gamucci T, Ciardiello F, . Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: The GEmcitabine-COxib in NSCLC (GECO) study. Lancet Oncol 2007;6: 500–12.
   Web of Science ®Google Scholar
• Dawson SJ, Michael M, Biagi J, Foo KF, Jefford M, Ngan SY, . A phase I/II trial of celecoxib with chemotherapy and radiotherapy in the treatment of patients with locally advanced oesophageal cancer. Invest New Drugs 2007;2:123–9.
   Google Scholar
• Jackson NA, Barrueco J, Soufi-Mahjoubi R, Marshall J, Mitchell E, Zhang X, . Comparing safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer: Findings from the bolus, infusional, or capecitabine with camptostar-celecoxib study. Cancer 2009;12:2617–29.
   Web of Science ®Google Scholar
• Preston T, Fearon KC, McMillan DC, Winstanley FP, Slater C, Shenkin A, . Effect of ibuprofen on the acute-phase response and protein metabolism in patients with cancer and weight loss. Br J Surg 1995;2:229–34.
   Web of Science ®Google Scholar
• Shinohara N, Kumagai A, Kanagawa K, Maruyama S, Abe T, Sazawa A, . Multicenter phase II trial of combination therapy with meloxicam, a COX-2 inhibitor, and natural interferon-alpha for metastatic renal cell carcinoma. Jap J Clin Oncol 2009;11:720–6.
   Web of Science ®Google Scholar
• Creagan ET, Buckner JC, Hahn RG, Richardson RR, Schaid DJ, Kovach JS. An evaluation of recombinant leukocyte A interferon with aspirin in patients with metastatic renal cell cancer. Cancer 1988;61:1787–91.
   PubMed Web of Science ®Google Scholar
• Wigmore SJ, Falconer JS, Plester CE, Ross JA, Maingay JP, Carter DC, . Ibuprofen reduces energy expenditure and acute-phase protein production compared with placebo in pancreatic cancer patients. Br J Cancer 1995;1:185–8.
   Web of Science ®Google Scholar
• Hyltander A, Korner U, Lundholm KG. Evaluation of mechanisms behind elevated energy expenditure in cancer patients with solid tumours. Eur J Clin Invest 1993;23:46–52.
   PubMed Web of Science ®Google Scholar
• Mantovani G, Madeddu C, Maccio A, Gramignano G, Lusso MR, Massa E, . Cancer-related anorexia/cachexia syndrome and oxidative stress: An innovative approach beyond current treatment. Cancer Epidemiol Biomarkers Prev 2004;13:1651–9.
   PubMed Web of Science ®Google Scholar
• Lindholm E, Daneryd P, Körner U, Hyltander A, Fouladiun M, Lundholm K. Effects of recombinant erythropoietin in palliative treatment of unselected cancer patients. Clin Cancer Res 2004;20:6855–64.
   Web of Science ®Google Scholar
• Daneryd P. Epoetin alfa for protection of metabolic and exercise capacity in cancer patients. Semin Oncol 2002; 29 (3 Suppl 8):69–74.
   PubMed Web of Science ®Google Scholar
• Lundholm K, Gelin J, Hyltander A, Lonnroth C, Sandstrom R, Svaninger G, . Anti-inflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors. Cancer Res 1994;54:5602–6.
   PubMed Web of Science ®Google Scholar
• Lundholm K, Daneryd P, Bosaeus I, Körner U, Lindholm E. Palliative nutritional intervention in addition to cyclooxygenase and erythropoietin treatment for patients with malignant disease: Effects on survival, metabolism, and function. Cancer 2004;9:1967–77.
   Web of Science ®Google Scholar
• Lundholm K, Daneryd P, Korner U, Hyltander A, Bosaeus I. Evidence that long-term COX-treatment improves energy homeostasis and body composition in cancer patients with progressive cachexia. Int J Oncol 2004;24:505–12.
   PubMed Web of Science ®Google Scholar
• Lai V, George J, Richey L, Kim HJ, Cannon T, Shores C, . Results of a pilot study of the effects of celecoxib on cancer cachexia in patients with cancer of the head, neck, and gastrointestinal tract. Head Neck 2008;30: 67–74.
   PubMed Web of Science ®Google Scholar
• Maccio A, Madeddu C, Gramignano G, Mulas C, Floris C, Sanna E, . A randomized phase III clinical trial of a combined treatment for cachexia in patients with gynecological cancers: Evaluating the impact on metabolic and inflammatory profiles and quality of life. Gynecol Oncol Epub 2011 Dec 27.
   Google Scholar
• Mantovani G, Maccio A, Madeddu C, Gramignano G, Lusso MR, Serpe R, . A phase II study with antioxidants, both in the diet and supplemented, pharmaconutritional support, progestagen, and anti-cyclooxygenase-2 showing efficacy and safety in patients with cancer-related anorexia/cachexia and oxidative stress. Cancer Epidemiol Biomarkers Prev 2006;15:1030–4.
   PubMed Web of Science ®Google Scholar
• Mantovani G, MacCio A, Madeddu C, Serpe R, Antoni G, Massa E, . Phase II nonrandomized study of the efficacy and safety of COX-2 inhibitor celecoxib on patients with cancer cachexia. J Mol Med 2010;88:85–92.
   PubMed Web of Science ®Google Scholar
• Cerchietti LC, Navigante AH, Peluffo GD, Diament MJ, Stillitani I, Klein SA, . Effects of celecoxib, medroxyprogesterone, and dietary intervention on systemic syndromes in patients with advanced lung adenocarcinoma: A pilot study. J Pain Symptom Manage 2004;27:85–95.
   PubMed Web of Science ®Google Scholar
• Cerchietti LC, Navigante AH, Castro MA. Effects of eicosapentaenoic and docosahexaenoic n-3 fatty acids from fish oil and preferential Cox-2 inhibition on systemic syndromes in patients with advanced lung cancer. Nutr Cancer 2007;59:14–20.
   PubMed Web of Science ®Google Scholar
• McMillan DC, O’Gorman P, Fearon KC, McArdle CS. A pilot study of megestrol acetate and ibuprofen in the treatment of cachexia in gastrointestinal cancer patients. Br J Cancer 1997;76:788–90.
   PubMed Web of Science ®Google Scholar
• McMillan DC, Wigmore SJ, Fearon KC, O’Gorman P, Wright CE, McArdle CS. A prospective randomized study of megestrol acetate and ibuprofen in gastrointestinal cancer patients with weight loss. Br J Cancer 1999;79:495–500.
   PubMed Web of Science ®Google Scholar
• Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 1998;16:139–44.
   PubMed Web of Science ®Google Scholar
• Jones LW, Hornsby WE, Goetzinger A, Forbes LM, Sherrard EL, Quist M, . Prognostic significance of functional capacity and exercise behavior in patients with metastatic non-small cell lung cancer. Lung Cancer 2012;76:248–52.
   PubMed Web of Science ®Google Scholar
• McGettigan P, Henry D. Cardiovascular risk with non–steroidal anti-inflammatory drugs: Systematic review of population-based controlled observational studies. PLoS Med 2011;8:e1001098.
   Google Scholar
• Schlondorff D. Renal complications of nonsteroidal anti–inflammatory drugs. Kidney Int 1993;44: 643–53.
   PubMed Web of Science ®Google Scholar
• Cahlin C, Korner A, Axelsson H, Wang W, Lundholm K, Svanberg E. Experimental cancer cachexia: The role of host-derived cytokines interleukin (IL)-6, IL-12, interferon-gamma, and tumor necrosis factor alpha evaluated in gene knockout, tumor-bearing mice on C57 Bl background and eicosanoid-dependent cachexia. Cancer Res 2000;60: 5488–93.
   PubMed Web of Science ®Google Scholar
• Yao M, Zhou W, Sangha S, Albert A, Chang AJ, Liu TC, . Effects of nonselective cyclooxygenase inhibition with low-dose ibuprofen on tumor growth, angiogenesis, metastasis, and survival in a mouse model of colorectal cancer. Clin Cancer Res 2005;11:1618–28.
   PubMed Web of Science ®Google Scholar
• Ninomiya I, Nagai N, Oyama K, Hayashi H, Tajima H, Kitagawa H, . Antitumor and anti-metastatic effects of cyclooxygenase-2 inhibition by celecoxib on human colorectal carcinoma xenografts in nude mouse rectum. Oncol Report 2012;28:777–84.
   PubMed Web of Science ®Google Scholar
• Baris D, Karagas MR, Koutros S, Colt JS, Johnson A, Schwenn M, . Non-steroidal anti-inflammatory drugs (NSAIDs) and other analgesic use and bladder cancer in northern New England. Int J Cancer Epub 2012 Apr 17.
   Google Scholar
• Brasky TM, Potter JD, Kristal AR, Patterson RE, Peters U, Asgari MM, . Non-steroidal anti-inflammatory drugs and cancer incidence by sex in the VITamins And Lifestyle (VITAL) cohort. Cancer Cause Control 2012;23: 431–44.
   PubMed Web of Science ®Google Scholar
• Groen HJ, Sietsma H, Vincent A, Hochstenbag MM, van Putten JW, van den Berg A, . Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with advanced non-small-cell lung cancer: The NVALT-4 study. J Clin Oncol 2011;29: 4320–6.
   PubMed Web of Science ®Google Scholar
• Davis TW, Zweifel BS, O’Neal JM, Heuvelman DM, Abegg AL, Hendrich TO, . Inhibition of cyclooxygenase-2 by celecoxib reverses tumor-induced wasting. J Pharmacol Exp Therapeut 2004;308:929–34.
   PubMed Web of Science ®Google Scholar
• Peluffo GD, Stillitani I, Rodriguez VA, Diament MJ, Klein SM. Reduction of tumor progression and paraneoplastic syndrome development in murine lung adenocarcinoma by nonsteroidal antiinflammatory drugs. Int J Cancer 2004;110:825–30.
   PubMed Web of Science ®Google Scholar
• Fearon KC, Glass DJ, Guttridge DC. Cancer cachexia: Mediators, signaling, and metabolic pathways. Cell Metab Epub 2012 Jul 17.
   Google Scholar
• Grosser T. Variability in the response to cyclooxygenase inhibitors: Toward the individualization of nonsteroidal anti-inflammatory drug therapy. J Invest Med 2009;57: 709–16.
   PubMed Web of Science ®Google Scholar
• Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Breazna A, Kim K, . Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial. Cancer Prev Res 2009;2:310–21.
   PubMed Web of Science ®Google Scholar
• Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger PM, . Cardiovascular safety of non-steroidal anti-inflammatory drugs: Network meta–analysis. BMJ 2011;342:c7086.
   Google Scholar